C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma.
Standard
C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma. / Mahner, Sven; Baasch, C; Schwarz, J; Hein, Sybill; Wölber, L; Jänicke, Fritz; Milde-Langosch, Karin.
in: BRIT J CANCER, Jahrgang 99, Nr. 8, 8, 2008, S. 1269-1275.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma.
AU - Mahner, Sven
AU - Baasch, C
AU - Schwarz, J
AU - Hein, Sybill
AU - Wölber, L
AU - Jänicke, Fritz
AU - Milde-Langosch, Karin
PY - 2008
Y1 - 2008
N2 - Members of the Fos protein family dimerise with Jun proteins to form the AP-1 transcription factor complex. They have a central function in proliferation and differentiation of normal tissue as well as in oncogenic transformation and tumour progression. We analysed the expression of c-Fos, FosB, Fra-1 and Fra-2 to investigate the function of Fos transcription factors in ovarian cancer. A total of 101 patients were included in the study. Expression of Fos proteins was determined by western blot analysis, quantified by densitometry and verified by immunohistochemistry. Reduced c-Fos expression was independently associated with unfavourable progression-free survival (20.6, 31.6 and 51.2 months for patients with low, moderate and high c-Fos expression; P=0.003) as well as overall survival (23.8, 46.0 and 55.5 months for low, moderate and high c-Fos levels; P=0.003). No correlations were observed for FosB, Fra-1 and Fra-2. We conclude that loss of c-Fos expression is associated with tumour progression in ovarian carcinoma and that c-Fos may be a prognostic factor. These results are in contrast to the classic concept of c-Fos as an oncogene, but are supported by the recently discovered tumour-suppressing and proapoptotic function of c-Fos in various cancer types.
AB - Members of the Fos protein family dimerise with Jun proteins to form the AP-1 transcription factor complex. They have a central function in proliferation and differentiation of normal tissue as well as in oncogenic transformation and tumour progression. We analysed the expression of c-Fos, FosB, Fra-1 and Fra-2 to investigate the function of Fos transcription factors in ovarian cancer. A total of 101 patients were included in the study. Expression of Fos proteins was determined by western blot analysis, quantified by densitometry and verified by immunohistochemistry. Reduced c-Fos expression was independently associated with unfavourable progression-free survival (20.6, 31.6 and 51.2 months for patients with low, moderate and high c-Fos expression; P=0.003) as well as overall survival (23.8, 46.0 and 55.5 months for low, moderate and high c-Fos levels; P=0.003). No correlations were observed for FosB, Fra-1 and Fra-2. We conclude that loss of c-Fos expression is associated with tumour progression in ovarian carcinoma and that c-Fos may be a prognostic factor. These results are in contrast to the classic concept of c-Fos as an oncogene, but are supported by the recently discovered tumour-suppressing and proapoptotic function of c-Fos in various cancer types.
M3 - SCORING: Zeitschriftenaufsatz
VL - 99
SP - 1269
EP - 1275
JO - BRIT J CANCER
JF - BRIT J CANCER
SN - 0007-0920
IS - 8
M1 - 8
ER -
